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Microglia are multifunctional immune cells in the central nervous system (CNS). In the neurodegenerative diseases such as
Alzheimer’s disease (AD), accumulation of glial cells, gliosis, occurs in the lesions. The role of accumulated microglia in the
pathophysiology of AD is still controversial. When neuronal damage occurs, microglia exert diversiﬁed functions, including
migration,phagocytosis,andproductionofvariouscytokinesandchemokines.Amongthese,microglialphagocytosisofunwanted
neuronal debris is critical to maintain the healthy neuronal networks. Microglia express many surface receptors implicated in
phagocytosis. It has been suggested that the lack of microglial phagocytosis worsens pathology of AD and induces memory
impairment. The present paper summarizes recent evidences on implication of microglial chemotaxis and phagocytosis in AD
pathology and discusses the mechanisms related to chemotaxis toward injured neurons and phagocytosis of unnecessary debris.
1.Introduction
Microglia are macrophage-like resident immune cells in the
central nervous system (CNS) and possess both neurotoxic
and neuroprotective function. Microglia accumulate in the
lesions of a variety of neurodegenerative disorders, such as
Alzheimer’s disease (AD), Parkinson’s disease, and multiple
sclerosis, and are thought to play both toxic and protective
functions for neuronal survival [1]. Microglia are considered
to be a ﬁrst line defense and respond quickly to various
stimuli. When activated, microglia undergo morphological
changes to ameboid, proliferate, migrate toward injured
areas, and release many soluble factors and phagocytosis
of foreign substances or unwanted self-debris. Appropriate
migration of microglia to damaged area is controlled by
chemokines and nucleotide ATP [2, 3]. Phagocytosis seems
tobeimportanttopreventthesenileplaqueexpansioninAD
by removing amyloid β (Aβ)d e p o s i t[ 4]. Microglia not only
engulf the Aβ protein but also phagocytose apoptotic cells
and degenerated neuronal debris. Phagocytosis of apoptotic
or degenerated neuronal debris is crucial to reduce inﬂam-
mation and maintain healthy neuronal networks. Another
type of phagocytosis, phagocytosis with inﬂammation, oc-
curs in chronic inﬂammatory-related neurodegenerative dis-
orders including Alzheimer disease [5–7].
Degenerated neurons releases several signaling molecu-
les, including nucleotides, cytokines, and chemokines, to
recruit microglia and enhance their activities [8, 9]. The
phenomenon are now termed as ﬁnd-me, eat-me, and help-
me signals. In this paper, we focused on ﬁnd-me, and eat-me
signals from degenerated neurons to microglia. Most distin-
guished and examined eat-me signal is phosphatidylserine
(PS), which is a component of cellular membrane and is
evertedonapoptoticcellmembrane[10,11].Nucleotidesare
alsoconsideredastheeat-mesignallately;microgliaexpresse
various P2X and P2Y receptors, nucleotide receptors, which
regulate not only chemotaxis but also phagocytosis [8, 12].
Microglia express many other surface receptors, which
have direct interaction with the target to initiate phagocy-
tosis, including PS receptor [6], lipopolysaccharide (LPS)
receptor CD14 [13], the scavenger receptor CD36 [14], the
purine receptor P2Y6 [8], and the toll-like receptors (TLRs)
[15]( Table 1, Figure 1). Another surface receptor, the CX3C2 International Journal of Alzheimer’s Disease
Table 1: Various chemotaxis or phagocytosis-related receptors in microglia and its ligand(s) or interacted factors. Microglia are activated
with various stimuli through the speciﬁc receptor of each stimuli. For detailed review of chemokines, pathogens, and factors associated with
tissue damage recognized by microglia, refer to [19–21].
Receptor type Subtypes Ligand(s)/interacted factors
CCR1
CCL3 (MIP-1α), CCL5 (RANTES), CCL7 (MCP-3),
CCL9 (MIP-1γ), CCL14 (HCC-1), CCL15 (HCC-2/leukotactin-1),
CCL16 (HCC-4/LEC), CCL23 (MPIF-1)
Chemokine receptor CCR2 CCL2 (MCP-1), CCL7 (MCP-3), CCL8 (MCP-2), CCL13 (MCP-4),
CCL16 (HCC-4/LEC)
CCR5 CCL3 (MIP-1α), CCL4 (MIP-1β), CCL5 (RANTES)
CXCR3 CXCL9 (Mig), CXCL10 (IP-10), CXCL11 (I-TAC)
CX3CR1 CX3CL1 (Fractalkine)
Purinergic receptor P2X4, P2Y7, P2Y12
P2Y6
ATP, ADP
UDP
TLR
TLR1
TLR2
TLR4
TLR6
TLR9
Triacyl lipopeptides
Glycolipids, Hsp70, HMGB1, Aβ
LPS, Hsp
Diacyl lipopeptides
CpG-DNA
Phosphatidylserine (PS) receptor MFG-E8, Tim1, Tim4
RAGE
PS of apoptotic cells
Aβ,A G E ,H M G B 1P So fa p o p t o t i cc e l l s
Scavenger receptor (SR) SR-AI/II (CD204), SR-BI, CD36 Cellular debris, apoptotic cells, Aβ (CD36)
Immunoglobulin (Ig) receptor FcγRI, FcγRIII Ig-opsonized particles
Complement receptor (CR) CR3 (MAC-1; CD11b/CD18) Complement components, opsonized particles
Other phagocytosis-related receptor
CD14
CD47
CD200R
TREM2
LPS, Aβ
SIRPα (CD172a)
CD200
Hsp60, DAP12
chemokine fractalkine receptor CX3CR1, is almost exclu-
sively expressed in microglia throughout the CNS, which
is involved in progression of neurodegenerative disease by
altering microglial activities [16, 17]( Figure 2). Deletion
of CX3CR1 expression in microglia results in progressive
neuronal cell death in an animal model of neurodegenerative
disease, by inducing microglial dysfunction. It has been
identiﬁed recently that neurons themselves produce cytokine
and chemokine, such as fractalkine. As shown in Figure 2,
we previously reported that interleukin-34 (IL-34), a newly
discovered cytokine, is produced by neurons, and that its
receptor, colony-stimulating factor 1 receptor, is primarily
expressed on microglia [18]. Fractalkine and IL-34 might be
importantmediatorbetweenneuronsandmicroglia,anditis
important to clarify this cellular crosstalk signaling pathways
for seeking future therapeutic target of neurodegenerative
diseases including AD. In the following sections, we will
discuss about recent advances of microglial chemotaxis and
phagocytosis and their implications for AD therapy.
2.MicroglialChemotaxisinCNS Injury
Chemokine and its receptors are expressed in broad area of
the CNS. The expression levels were increased under path-
ological conditions, which seem to facilitate the recruit-
ment and traﬃcking of glial cells to the damaged area [22].
Microglia constitutively express several chemokine receptors
(Table 1), which are implicated in the recruitment and ac-
cumulation microglia in AD lesions. When exposed to Aβ,
microglia are induced to produce several chemokines, such
as CCL2, CCL4, and CXCL12 [23]. CCR2, the receptor of
CCL2, deﬁciency resulted in reduction of microglial accu-
mulation and higher brain Aβ levels in mouse model of
AD, which might be mediated via suppression of anti-in-
ﬂammatory molecule, transforming growth factor β (TGF-
β)[ 3]. However, there is a conﬂicting report showing
increased TGF-β signaling in microglia surrounding Aβ
plaques in CCR2 knockout in AD model mouse (APPSwe/
PS1/CCR2−/−)[24].TheotherchemokinereceptorCX3CR1
expression in microglia was also increased in the mice.
This AD model has been shown to have accumulation of
oligomeric Aβ and memory impairment [24]. CX3CR1 is
the sole receptor of CX3C chemokine CX3CL1 (fractalkine).
The roles of CX3CL1-CX3CR1 signaling on AD pathology
are discussed in next section. CCL2 expression level is
also related to another neurodegenerative disorder, multiple
sclerosis (MS); CCL2 level is downregulated in cerebrospinal
ﬂuid from MS patients [25].
CCL21 is a neuronal chemokine, expressed in neurons.
Expression of CCL21 is upregulated in neurons undergoing
degeneration [26, 27]. CCL21 triggers chemotaxis of mi-
croglia through CXCR3, but not CCR7 which implicated in
peripheral lymphoid organs [28].
CXCR3-CXCL10 interaction is also implicated in mi-
croglial migration [29]. CXCR3 knockout mice reveal im-
pairment of the microglial migration but no change in pro-
liferation.CXCL10isalsoexpressedinneurons.CXCL10and
CCL21 synergistically induce microglial homing throughInternational Journal of Alzheimer’s Disease 3
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Figure 1: Chemotaxis or phagocytosis-involved receptors in microglia and correlation of the inﬂammatory or anti-inﬂammatory response.
Manyofthereceptorscorrelatedwithmicroglialactivitiesofchemotaxis(migration)orphagocytosis,respectively.Amongthese,someofthe
receptors possess not merely single function; CCR1 is the migration-inducing receptor that also possesses phagocytotic activity. CCR2 and
CCR5 are also the migration-inducting receptors that lead to anti-inﬂammatory response. CX3CR1 contributes to migration, phagocytosis,
and anti-inﬂammatory response. TREM2 and MFG-E8 induce phagocytosis and anti-inﬂammatory response. CD47 and CD200R usually
inducephagocytosisunderpathologicalcondition,sothattheyindirectlycontributetoanti-inﬂammatorystatus.TLR9activatesmicrogliato
inducephagocytosiswithproducingproinﬂammatoryandanti-inﬂammatorymolecules.Therearereceptorsinducingnotonlyphagocytosis
but also inﬂammatory response (CD14, CD36, RAGE, TLR1, TLR2, TLR4, and TLR6). Within these receptors that the synergistic signaling
involved Aβ-triggering inﬂammatory response are CD14-TLR2-TLR4 and CD36-TLR2-TLR6.
the receptor CXCR3 [30]. CXCL10 inhibits CCL21-induced
migration in microglia through CXCR3 [31]. Neuronal
CCL21 upregulates P2X4 receptor, the nucleotide receptor,
expressed in microglia [32]. This cascade is implicated in
pathophysiology of tactile allodynia to cause chronic neuro-
pathic pain.
CCR5 also plays a role in neuronal survival [33]. In is-
chemic stroke models, brain damage is severer by CCR5 deﬁ-
ciency [34].
Inter- and intracellular transmitter nucleotides can in-
ﬂuence microglial migration and phagocytosis. Microglia
express various nucleotide receptors, P2X and P2Y receptors
(Table 1)[ 35]. Aβ-induced microglial activation is mediated
through P2X7 receptor that is reported as proinﬂammatory
response conductive receptor [36]. ATP predominantly
induced microglial migration among nucleotides through
P2Y receptors, especially P2Y12 [2, 37]. Following CNS
injury, expression of P2Y12 in microglia drastically reduced
after microglial activation, suggesting that P2Y12 is a pri-
mary and temporary receptor to induce microglial chemo-
taxis at early stages of the local CNS injury [37]. The other
nucleotide UDP increases mainly microglial phagocytosis
(uptake of microspheres) via P2Y6 receptor [8]. In the
condition brain damage by kainic acid administration, the
P2Y6 receptor is upregulated and can act as a sensor for
phagocytosis [38].
3.CX3CL1-CX3CR1
The CX3C chemokine CX3CL1 (fractalkine, also called
as neurotactin), which has been identiﬁed as two forms,
soluble or membrane-anchored forms, plays a pivotal role
in signaling between degenerating neurons and microglia
[39]. CX3CL1 and its receptor CX3CR1 are highly expressed
in brain tissue, particularly in neurons and microglia [40–
42]. CX3CL1 directly induces various microglial functions
including migration [41], proliferation [43], inhibition of
Fas-ligand-induced cell death [44] and glutamate-induced
neurotoxicity [45, 46], and inhibition of proinﬂammatory
cytokine production [42, 47]. Recently, we have shown that
soluble form of CX3CL1 also directly enhances microglial
clearance of degenerated neuronal debris, which is mediated4 International Journal of Alzheimer’s Disease
Neuroprotection
Degradation of Aβ
Phagocytosis Antioxidant eﬀects
HO-1
Nrf2
ERK
MFG-E8
CSF1R
IDE IL-34
FKN
(membrane form)
Damaged
neuron
Cleavage
CX3CR1
Proliferation
Glutamate
JNK
Aβ
sFKN
(soluble form)
Microglia
?
“Eat-me signal” “Help-me signal”
Figure 2: Model of the role of neuronal chemokine (FKN) and neuronal cytokine (IL-34) in microglial phagocytosis and neuroprotection.
Neuronal cells primary produce chemokine fractalkine (CX3CL1; FKN) and cytokine IL-34. Microglia predominantly express its receptor,
CX3CR1, and colony-stimulating factor 1 receptor (CSF1R). Soluble form of FKN (sFKN) is secreted from damaged neurons and promotes
microglial phagocytosis of neuronal debris through the release of MFG-E8. sFKN also induces the expression of the antioxidant enzyme
HO-1 in microglia via Nrf2 recruitment and activation of the JNK MAPK signaling pathway. The neuroprotective eﬀects of sFKN are also
mediated in part by activation of ERK MAPK, although the downstream signaling pathway has not yet been elucidated. IL-34 promoted
microglial proliferation and clearance of Aβ which mediates insulin-degrading enzyme (IDE) expression. Therefore, sFKN and IL-34 may
be an intrinsic neuroprotectant for damaged yet surviving neurons.
through phosphatidylserine (PS) receptor and production
of Milk fat globule-EGF factor 8 protein (MFG-E8) [46]
(Figure 2). The source of soluble form of CX3CL1 is
neuron. The membrane-anchored CX3CL1 is cleaved by
several proteases including a disintegrin and metalloprotease
(ADAM) family, ADAM-10 and ADAM-17 [48–50], and
cathepsin S [51]. When neurons are injured or exposed to
glutamate,sheddingofCX3CL1occursimmediately[41,52].
However, little is known about direct connection with Aβ-
induced neuronal toxicity and the CX3CL1-shedding.
Another important function of ADAM family enzyme,
except for CX3CL1 shedding, is an α-secretase. It cleaves
APP in the centre of the Aβ domain, and generated α-APP
is considered to have neurotrophic function [53–56]. The
ADAMs include ADAM-9, ADAM-10, and ADAM-17 [57,
58].CathepsinSisexpressedpredominantlyinmicrogliaand
implicated in microglial activation of neuropathic pain [51].
Therefore, these CX3CL1-shedding proteases may regulate
the microglial phagocytosis directly or indirectly through
CX3CL1expression,andmayalsoplayaroleonpathogenesis
of AD.
Microglia respond to CX3CL1 through CX3CR1. In
a previous study, we have shown that CX3CL1 functions
neuroprotective against activated microglia-induced neuro-
toxicity [46]. There are some reports showing that CCL2
activates CX3CR1 expression, and the induction of CX3CR1
expression by CCL2-CCR2 axis is mediated through p38
MAPK activation [59]. CX3CR1 deﬁciency increases sus-
ceptibility to neurotoxicity in mouse models of Parkinson’s
disease, amyotrophic lateral sclerosis, and systemic LPS
administration [16]. CX3CL1-induced neuroprotection in
a rat model of Parkinson’s disease has also been reported
recently [60]. In addition, there are some reports showing
that pathologic features of AD mouse model are worsened
by knockout of CX3CR1 [17, 61].
4.MicroglialReceptorsInvolving
Phagocytosis withor without Inﬂammation:
Possible Implicationto AD Pathology
Microglial phagocytosis is classiﬁed into two categories, with
or without inﬂammation [62]. Some receptors are involved
in both types of phagocytosis (Table 1). The receptor leading
to inﬂammatory status includes CD14, CD36, the receptor
for advanced glycation end products (RAGEs), and toll-
like receptor (TLR) 1, TLR2, TLR4, and TLR6. The recep-
tor leading to anti-inﬂammatory status includes triggering
receptor expressed on myeloid cells 2 (TREM2) and PS
receptor (PSR), MFG-E8. Microglia also express many other
phagocytosis-related receptors which are not yet unclear to
the correlation of inﬂammatory status.International Journal of Alzheimer’s Disease 5
CR3. Microglia express classical phagocytosis-related recep-
tor, the αMβ2 integrin complement-receptor-3 (CR3; MAC-
1; CD11b/CD18), and scavenger-receptor (SR)-AI/II (SR-
AI/II; CD204). CR3 synergistically activated SR-AI/II-
mediated myelin phagocytosis by microglia [63, 64]. CR3
is implicated in clearance of bacteria through induction of
major histocompatibility complex class II (MHC II) antigens
[65]. CR3 is involved in endocytosis in normal conditions
and MHC II antigens in an inﬂammatory state. Microglia
express SR-AI/II and SR-BI during neonatal period, while in
adult they lack the expression. However SR-AI/II expression
in microglia is upregulated in AD [66].
CD14. CD14 is the LPS receptor which is also considered
as classical phagocytosis-related receptor in macrophage and
microglia [67]. CD14-mediated phagocytosis of apoptotic
cells occurred in both normal and inﬂammatory conditions
[67]. CD14-mediated phagocytosis does not require expres-
sion of PS receptor and possibly induces inﬂammatory con-
ditionsthroughactivationofCD14signaling[68].CD14also
contributes phagocytosis of Aβ by microglia [13]. However,
deletion of CD14 reportedly attenuates pathological features
of AD mouse model. The authors suggested that it might be
due to reduction of insoluble, but not soluble, Aβ [69].
FcγReceptor. Exposure of ﬁbrillar Aβ to microglia induces
phagocytosis through the receptors distinct from those used
by the classical phagocytosis: immunoglobulin receptors
(FcγRI and FcγRIII) or complement receptors [70].
CD36 and CD47. Aβ directly interacted with microglial cell
surface receptor complex comprising the class B scavenger
receptor CD36, α6β1 integrin, and integrin-associated pro-
tein CD47, all of them involved in migration and phago-
cytosis of microglia [70–72]. CD36 is required for ﬁbrillar
Aβ-induced chemotaxis and proinﬂammatory molecules
including reactive oxygen species (ROS), TNFα,I L - 1 β,a n d
several chemokines in microglia [23]. Aβ activates microglial
recruitment to amyloid deposition site through CD36-
dependent signaling cascade involving the Src kinase family
members, Lyn and Fyn, and the ERK1/2 [73]. CD47 is a
membrane glycoprotein, broadly expressed in the various
cell types in the CNS, including neurons and microglia.
Signal regulatory protein-α (SIRPα; CD172a) is a receptor
binding to CD47, which is also expressed on neurons
and myeloid cells. SIRPα is an inhibitory molecule of
CD47 that downregulates MAPK phosphorylation which
is a downstream pathway of CD47 [74]. SIRPα interacts
with the protein tyrosine phosphatases SHP-1 and SHP-2,
which are predominantly expressed in neurons, dendritic
cells,andmacrophages[75].IntactmyelinexpressesCD47to
suppress myelin phagocytosis by microglia via SIRPα-CD47
interaction [76]. Therefore, CD47 functions normally as a
marker of “self” to protect intact body component [76, 77].
RAGE. In has been reported that the direct interaction
of Aβ peptide with the receptor for RAGE is important
in AD pathophysiology. In AD brains, RAGE expression
is increased, and RAGE directly induces neurotoxicity by
production of oxidative stressors and indirectly by activating
microglia [78]. RAGE increases macrophage-colony stim-
ulating factor (M-CSF) from neurons via nuclear-factor-
κB- (NF-κB-) dependent pathway and released M-CSF
induced interaction of cognate receptor c-fms on microglia
which prolongs survival of microglia [79]. RAGE recognizes
multiple ligands other than Aβ peptide, such as advanced
glycation end products (AGEs), PS, and high-mobility group
box 1 protein (HMGB1) [80, 81]. These molecules act as
an agonist of RAGE on microglia, by inducing proinﬂam-
matory molecules, such as NO, TNF-α,I L - 1 β, and IL-6,
via MAP-kinase-kinase (MEK) and phosphatidylinositol 3-
kinase (PI3K) pathways [81]. Activation of RAGE leaded
to NF-κB and MAPK-mediated signaling to propagate and
perpetuate inﬂammation status [82]. RAGE also mediates
the transport of peripheral Aβ into the brain across the
blood-brain barrier (BBB) [83].
CD200R. CD200 is a transmembrane glycoprotein and is
e x p r e s s e do nm a n yd i ﬀerent cell types including neurons,
endothelial cells, lymphocytes, and dendritic cells [84]. The
receptor of CD200, CD200R expression, is predominant
in myeloid cells, macrophages, and microglia [84, 85].
As in the case of SIRPα-CD47, CD200 exerts inhibitory
eﬀect on CD200R, so that CD200-CD200R interaction can
downregulate activity of microglia. In retina, it has been
shown thatactivation of CD200R in microglia does not show
direct eﬀect on migration, but CD200-CD200R signaling
restores LPS/IFNγ-induced loss of migration [86]. CD200
knockout leads to an expansion of the myeloid population
in several tissues and increased expression of the activation
markersinmicroglia,includingthesignalingadaptorprotein
DNAX-activatingproteinof12kDa(DAP12),CD11b,CD45,
CD68, and inducible NO synthase (iNOS) [87]. Blocking
of CD200R increases neurodegeneration in mouse model
of Parkinson’s disease [88]. These observations suggest
that CD200-CD200R signaling leads to anti-inﬂammatory
state and protection against neurotoxic stimuli. CD200 and
CD200R expression levels (neurons and microglia, resp.)
are decreased in AD hippocampus and inferior temporal
gyrus, indicating that inhibition of CD200-CD200R axis
contributes to AD pathology [89].
TREM2. TREM2, a recently identiﬁed innate immune
receptor, and its adaptor protein DAP12 are expressed on
microglia and cortical neurons, but not on hippocampal
neurons, astrocytes, and oligodendrocytes. Their expression
correlates with clearance of apoptotic neurons by microglia
withoutinﬂammation[90–92].However,endogenousligand
or speciﬁc agonist of TREM2 had not been identiﬁed until
recently. Heat shock protein 60 (Hsp60) is a mitochondrial
chaperone, which interacts with TREM2 directly. Hsp60-
induced phagocytosis is only found in microglia which have
robust expression of TREM2 [93]. In AD model mouse,
TREM2 expression was highest in the outer zone in Aβ
plaques, and the expression level correlated with the size
of Aβ plaque [94]. Forced expression of TREM2 positively6 International Journal of Alzheimer’s Disease
regulated microglial phagocytosis, the ability of microglia
to stimulate CD4+ T-cell proliferation, TNF-α and CCL2
production, but not IFNγ production [94].
5. TLRs
TLRs are class of pattern-recognition receptors in the innate
immune system to induce inﬂammatory responses. 13 TLRs
have been identiﬁed in human and mouse to date, except for
TLR10 which is expressed only in human [95, 96]. TLRs may
also contribute to the microglial inﬂammatory response to
promote AD pathogenesis [15].
CD11b, a marker of macrophages and microglia, has
been shown to interact with TLR signaling. CD11b knockout
mouse exhibited enhanced TLR-mediated responses and
subsequent more susceptibility to endotoxin shock [97].
Among the TLRs, LPS receptor TLR4 potently activates
microglia in various aspects, such as Aβ phagocytosis and
proinﬂammatory molecules production [98, 99]. Activa-
tion of TLR1, TLR2, TLR3, and TLR9 by each selective
agonist also increased phagocytosis and several cytokines
and chemokine production [98, 100]. CD14 is a coreceptor
of TLR4. The response of microglia to ﬁbrillar Aβ is
mediated via CD14, which act together with TLR4 and
TLR2 to bind ﬁbrillar Aβ and induced microglial activation
through p38 MAPK [101]. Deﬁciency of CD200 induces the
expression of TLR2 and TLR4 in glial cells and proliferation
of CD11b+/MHCII+/CD40+ activated microglia [102].
These mice show memory impairment, suggesting that dual
activation of TLR2 and TLR4 may induce an inﬂammatory
phenotype of microglia which negatively regulate synaptic
plasticity in the AD model. Aβ triggers the inﬂammatory
statusinmicrogliaviaheterodimerofTLR4andTLR6,which
is regulated by CD36 [103]. Therefore, CD14-TLR2-TLR4
and CD36-TLR4-TLR6 signaling are crucial to Aβ-induced
inﬂammatory response, and also in microglial phagocytosis.
Bacterial DNA containing motifs of unmethylated CpG
dinucleotides (CpG-DNA) is a ligand of TLR9, which is
initially identiﬁed to activate microglia and strongly induces
TNF-αandIL-12production[104].However,wehaveshown
that CpG activated microglia to produce neuroprotective
molecule, such as hemeoxygenase-1 (HO-1) and matrix
metalloproteinase9(MMP-9)withoutproducingneurotoxic
molecules, such as TNF-α, glutamate and nitric oxide (NO),
and enhanced Aβ clearance to protect memory disturbance
in vivo [105]. There are the discrepancies about CpG eﬀect
between aforementioned two reports despite using the same
origincells(mouseprimarymicroglia).Itmaybeduetocon-
centrations of this TLR9 ligand used: higher concentration
(10μM) in former report [104], whereas lower concentra-
tions(1to100nM)inlatterreport[105].Moreover,thelatter
report revealed the diﬀerence on neuroprotective eﬀect of
CpG among synthetic oligodeoxynucleotides (ODNs) classes
(A to C). Class A CpG did not activate microglia, but classes
B and C CpGs increased microglial neuroprotective eﬀect
through induction of clearance of Aβ a n dp r o d u c t i o no f
neuroprotectant. These suggested that the CpG sequence-
dependent microglial activation and responses are present.
CpG increased chemokine CCL9 and its receptor CCR1
expression in macrophages and microglia via TLR9/MyD88
signaling involving ERK, p38 MAPK, and PI3K pathways.
Thus it can enhance microglial migration as well as phago-
cytosis [106].
6.PSR
Phagocytotic cells recognize apoptotic cells by several mech-
anisms, including recognition of PS expressed on the cells.
PS is receiving much attention because it is responsible
for phagocytosis without inducing inﬂammation [10]. The
receptors of PS (PSRs) had not been clariﬁed for a long time
but have uncovered in recent years. These include MFG-E8
(the lactadherin homolog in humans) and T-cell immuno-
g l o b u l i nm u c i nd o m a i n4( T i m 4 )[ 107, 108]. These act
as a bridge between PS-expressing apoptotic cells and PSR
expressing phagocytes and trigger engulfment of cellular
debris.
MFG-E8 is expressed on various macrophage subsets in
the periphery and on microglia in the CNS. Recently, we
have shown that CX3CL1 induces MFG-E8 expression in
primary mouse microglia to lead to the microglial clearance
of degenerated neuronal debris [46]. Others also reported
the induction of MFG-E8 by CX3CL1 in macrophages and
rat microglia [109, 110]. MFG-E8 bridges PS and integrins
αvβ3 or αvβ5 on the surface of phagocytes [107, 111]. High-
mobility group box 1 protein (HMGB1) is an intracellular
protein that activates transcriptional factors, including p53
and NF-κB. HMGB1 reportedly suppresses the interaction
between MFG-E8 and αvβ3 integrin in macrophage and
inhibits the phagocytosis of apoptotic cells through ERK-
mediated signaling pathway [112]. MFG-E8 may also be
involvedinAβphagocytosis,sinceitsexpressionisreducedin
AD [113]. We previously showed the neutralization of MFG-
E8 progressed neuronal degeneration [46]. MFG-E8 report-
edly induces anti-inﬂammation status in the periphery.
Therefore, MFG-E8 may possibly lead to targeted clearance
of unwanted molecules, such as Aβ, without inﬂammation.
The other well-studied PSR, Tim4, is expressed in MAC-
1+ cells in various mouse tissues, including spleen, lymph
nodes, and fetal liver [108]. Among the other Tim family
members, Tim1, but neither Tim2 nor Tim3, also speciﬁcally
binds to PS. Tim1-PS subsequently connects with exosomes
to recognize and engulf apoptotic cells [114–116].
It has been shown recently that RAGE also recognizes
PS and induces apoptotic cell clearance [80]. However as
mentioned previously, RAGE-guided intracellular signaling
pathway induces prolonged inﬂammatory status.
7. γ-SecretaseandPhagocytosisin
ADPathology
γ-secretase is a protein complex of four essential membrane
proteins: aph-1, pen-2, nicastrin, and presenilin. A recent
study suggests that presenilin increases microglial phago-
cytosis of Aβ, and this γ-secretase has dual role for AD
pathogenesis: one is cleavage of amyloid precursor proteinInternational Journal of Alzheimer’s Disease 7
(APP) to produce pathologic Aβ, and the other is reduction
of microglial phagocytosis of Aβ by γ-secretase inhibitor
[117]. Vertebrates have two presenilin genes, PSEN1 (located
on chromosome 14 in humans; encoded presenilin 1) and
PSEN2 (located on chromosome 1; encoded presenilin 2).
There is a report that presenilin 2 is identiﬁed as the pre-
dominant γ-secretase in mouse microglia (but not preseni-
lin 1), which repressed microglial activation via its function
as a γ-secretase, and its expression is increased by inﬂamma-
tory stimuli (IFN-γ)[ 118].
In order to explore the detailed mechanism how γ-
secretase regulates microglial activity, further studies are
needed since γ-secretase is a therapeutic target for AD. In
traumaticinjuryofthebrain,presenilinandnicastrinexpres-
sionsareelevatedinactivatedmicrogliaandastrocytes[119].
γ-secretase mainly cleaves APP to lead to accumulation of
Aβ1-42, which then results in aggregation of Aβ protein to
worsen AD pathology. However Aβ1-42 is also a target of
microglial phagocytosis.
8. Concluding Remarks
Microglia express a wide array of receptors characteristic to
immune cell, such as CD molecules, integrins, chemokine
receptors, and PSR (Figure 1). These receptors are involved
in multiple functions of microglia. Chemokine receptors
not only induce migration of microglia but also con-
tribute directly to AD pathogenesis through regulation of
phagocytosis and neuroprotective activity. PS acts as eat-me
signal, and PSR-mediated phagocytosis so far is regarded as
inducing anti-inﬂammatory responses. However, according
to some recent reports, RAGE interacts with PSR and
facilitates phagocytosis with robust inﬂammation status [80,
120]. Therefore, if the other phagocytosis-related receptors
including TLRs interact with PSR, microglia would be
activated to outbreak excessive phagocytosis with robust
inﬂammation.
Microglia from old APP/PS1 mouse, but not from
younger ones, show the reduction of SRA, CD36, RAGE, and
the Aβ-degrading enzymes including insulysin, neprilysin,
andMMP9[121].Dysfunctionofmicrogliaafterprogression
of disease development may lead to neurodegeneration.
Thus, it is important to consider the microglial status
depending on the disease stage, to treat AD eﬀectively. As
shown in Figure 2, FKN and IL-34 may be an intrinsic
neuroprotectant for damaged but still surviving neurons
through activation of microglia. Therefore, it is important to
elucidate neurons-microglia crosstalk in neurodegenerative
condition.
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